Background. Patients diagnosed with Acute Myeloid Leukaemia (AML) often receive cytarabine-based chemotherapy as standard treatment. Cytarabine is usually given in combination with other agents such as idarubicin. Such treatments are known to cause hepatic dysfunction characterized by a combination of jaundice, hyperbilirubinemia and increases in liver enzymes. Isolated hyperbilirubinemia is rarely reported. It is often difficult to identify a causative agent for the hepatic dysfunction, as there are often complicating factors such as sepsis. Aim: To report a case of isolated hyperbilirubinemia in a patient treated with cytarabine-based chemotherapy for AML. Clinical Details. After a diagnosis of AML the patient was admitted to hospital to receive induction chemotherapy consisting of high-dose cytarabine, idarubicin, and etoposide. All baseline laboratory results were normal, except the full blood evaluation that was consistent with AML. The chemotherapy was delivered over 7 days, and on the eighth day the patient had a bilirubin (BL) level of 27 umol/L (normal range 522 umol/L). All other liver function tests (LFT) were normal. This isolated hyperbilirubinemia remained for the rest of the patient's admission, peaking on day 26, with a level of 255 umol/L. After a stay in the intensive care unit, the patient was discharged on day 45 with a bilirubin level of 33 umol/L. All other LFT remained unremarkable. Outcome. The isolated hyperbilirubinemia resolved slowly and on day 68, when the patient was re-admitted for further dose-reduced cytarabine, the BL level was 21 umol/L. The patient was successfully retreated with this lower dose regimen. Conclusion. Isolated hyperbilirubinemia is an uncommon presentation of cytarabine induced liver dysfunction. Resolution does occur but over a prolonged period. A lower dose of cytarabine for future treatment should be considered. J Oncol Pharm Practice (2009) 15: 107—110.
[1]
O. Altundag,et al.
Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia
,
2004,
American journal of hematology.
[2]
N. Kaplowitz,et al.
Drug-Induced Liver Injury
,
2004,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3]
C. Shanholtz,et al.
Acute life-threatening toxicity of cancer treatment.
,
2001,
Critical care clinics.
[4]
C. Day,et al.
The natural history of histologically proved drug induced liver disease
,
1999,
Gut.
[5]
H. Mohri,et al.
Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome.
,
1999,
Anti-cancer drugs.
[6]
A. Bonaventura.
Complications of cytotoxic therapy- part 2
,
1995
.
[7]
A. Bonaventura.
Complications of cytotoxic therapy -part 1
,
1995
.
[8]
A. Cortelezzi,et al.
Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
,
1989,
Seminars in Oncology.
[9]
J. Gabrilove,et al.
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
,
1989,
Seminars in oncology.
[10]
W. Woods,et al.
Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation.
,
1980,
The American journal of medicine.